Intramuscular<i>vs</i>intradermal route for hepatitis B booster vaccine in celiac children

Leonardi, ﻿Salvatore; Praticò, Andrea D.; Lionetti, Elena; Spina, Massimo; Vitaliti, Giovanna; Rosa, Mario La

doi:10.3748/wjg.v18.i40.5729

Cited by 48 publications

(45 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical trials with various other viral vaccines administered i.d. yielded promising data (11,12,21). However, poor immune responses have also been reported after i.d.…”

Section: Discussionmentioning

confidence: 94%

High-Level Cellular and Humoral Immune Responses in Guinea Pigs Immunized Intradermally with a Heat-Inactivated Varicella-Zoster Virus Vaccine

Sarkadi

Jankovics

Fodor

et al. 2015

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

V aricella-zoster virus (VZV) causes varicella by primary infection and herpes zoster by reactivation of the latent virus in the sensory ganglia of infected individuals. After primary infection, the immune response comprises VZV-specific antibody and T cell-mediated immunity (CMI), which are important for recovery from varicella. T cell responses are necessary to control latent VZV in the sensory ganglia. A lack or a declining level of CMI to VZV has been associated with a higher risk of development of herpes zoster (1).A varicella vaccine consisting of live, attenuated strain OKA (vOKA) has been developed in Japan and licensed for mass vaccination in Japan, South Korea, the United States, and several European countries or recommended for only selected groups of the population in other countries (2, 3). To prevent herpes zoster, a zoster vaccine containing 14 times as many PFU of vOKA than the varicella vaccine was developed and licensed for the vaccination of immunocompetent subjects older than 60 years in the United States in 2006 (4). Varicella and zoster vaccines are administered by the subcutaneous (s.c.) route. However, vaccination of immunocompromised individuals with live VZV vaccines can be problematic and different strategies for safe immunization need to be explored (5).Several clinical studies have indicated that the use of a heatinactivated VZV vaccine is an alternative mode of immunization of immunocompromised individuals. Triple vaccination of bone marrow transplant patients with a heat-inactivated varicella vaccine administered s.c. decreased the severity of herpes zoster (6) and four s.c. doses of a heat-inactivated zoster vaccine proved safe and immunogenic in patients with tumor malignancy, HIV-infected individuals, or hematopoietic stem cell transplant recipients (7). When healthy elderly subjects were immunized s.c. with a single dose of either live or heat-inactivated varicella vaccine, there were no differences in antibody responses or IFN-␥ production by peripheral blood mononuclear cells (8). These data indicated that a heat-inactivated VZV vaccine might be useful in preventing herpes zoster. However, protection against herpes zoster following immunization with either a live or heat-inactivated vaccine is not optimal and a more potent antigenic stimulus is needed to improve the efficacy of the vaccine in high-risk patients (9).The skin is a highly immunogenic organ (10). Noninvasive, needle-free liquid jet injection of liquid or powder into the skin has been used in clinical trials for immunization against viral infections (11-13). The barrier structure and thickness of the stratum corneum, the outermost layer of the skin, are similar in guinea pigs and humans (18.6 and 18.2 m, respectively) (14), and thus, the i.d. route of immunization and the effectiveness of a potential i.d. delivery device for humans can be tested in guinea pigs. Moreover, the parental OKA strain is attenuated in human

show abstract

“…Clinical trials with various other viral vaccines administered i.d. yielded promising data (11,12,21). However, poor immune responses have also been reported after i.d.…”

Section: Discussionmentioning

confidence: 94%

High-Level Cellular and Humoral Immune Responses in Guinea Pigs Immunized Intradermally with a Heat-Inactivated Varicella-Zoster Virus Vaccine

Sarkadi

Jankovics

Fodor

et al. 2015

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

“…Four weeks after every booster dose, 90% of ID patients and 96.4% of IM subjects showed a protective anti-HBs titer after a third booster dose. The authors concluded that both routes are efective in revaccinating CD patients; however, the ID route seems to produce a signiicantly higher percentage of higher responders [47].…”

Section: New Approaches In Hepatitis B Vaccination In Celiac Childrenmentioning

confidence: 99%

“…Data suggest that the ID route ofers greater immunogenicity due to direct delivery of antigen to the skin immune system, using even lower doses of antigen than IM route [47]. Moreover, the presence of a skin reaction on the site of the intradermal injection could represent a less expensive strategy to test serum anti-HBs response after the booster dose [48].…”

Section: New Approaches In Hepatitis B Vaccination In Celiac Childrenmentioning

confidence: 99%

Celiac Disease and HBV Vaccination

Anania¹,

Olivero²,

Olivero³

et al. 2017

Celiac Disease and Non-Celiac Gluten Sensitivity

View full text Add to dashboard Cite

Celiac disease (CD) is an immune-mediated systemic disorder elicited by gluten and related prolamins in genetically susceptible individuals, characterized by the presence of a variable combination of gluten-dependent clinical manifestations, CD-speciic antibodies, HLA-DQ2 and HLA-DQ8 haplotypes, and enteropathy. Hepatitis B virus (HBV) infection is an important global public health problem that can cause chronic liver disease, and it is associated to a high risk of death from cirrhosis and hepatocellular carcinoma. Since 1982, a safe and efective HBV vaccine has been available, and recommendation for HBV vaccination has been extended to all infants to achieve protection against HBV infection. HBV vaccination is highly efective in eliciting a sustained immune response in immune-competent individuals. However, research papers have suggested that celiac patients may have low rate of protective antibodies after HBV vaccination. The failure of CD subjects to respond to HBV vaccination has great importance for public health policies as the nonresponders could be regarded as a reservoir for HBV. The aim of our work is to revise and to discuss the scarce literature on this ield in order to provide clinical practice guidelines to establish the best surveillance program of response to HBV vaccine in CD pediatric patient.

show abstract

“…While this level is achieved in 85-100 % of the general population, titers reach acceptable levels in only 64 % of dialysis patients (Chaves et al 2011), 41-60 % of individuals positive for HIV (Landrum et al 2012;Laurence 2005), 35 % of individuals with irritable bowel disease (Vida Pérez et al 2009), 50 % of celiac disease patients (Ahishali et al 2008;Leonardi et al 2009), 38 % of obese individuals (Roome et al 1993), 30-58 % of the elderly (Roome et al 1993;Tohme et al 2011;Williams et al 2012), and 57 % of those with chronic kidney disease (Zitt et al 2011). There is some evidence that other routes of vaccine administration may be effective in eliciting responses in nonresponders, such as by intradermal administration in healthcare workers (Levitz et al 1995;Nagafuchi et al 1991;Roukens et al 2010) and in children with celiac disease (Leonardi et al 2012). Unfortunately the present commercial vaccines are not approved for intradermal administration and further resources will need to be allocated to pursue this healthcare model.…”

Section: Hepatitis B Epidemiologymentioning

confidence: 99%

An Oral Vaccine for Hepatitis B: Challenges, Setbacks, and Breakthroughs

Hayden

2014

Commercial Plant-Produced Recombinant Protein Products

View full text Add to dashboard Cite

Intramuscularvsintradermal route for hepatitis B booster vaccine in celiac children

Abstract: Our study suggests that both ID and IM routes are effective and safe options to administer a booster dose of HBV vaccine in celiac patients. However the ID route seems to achieve a greater number of high responders and to have a better cost/benefit ratio.

Cited by 48 publications

References 34 publications

High-Level Cellular and Humoral Immune Responses in Guinea Pigs Immunized Intradermally with a Heat-Inactivated Varicella-Zoster Virus Vaccine

High-Level Cellular and Humoral Immune Responses in Guinea Pigs Immunized Intradermally with a Heat-Inactivated Varicella-Zoster Virus Vaccine

Celiac Disease and HBV Vaccination

An Oral Vaccine for Hepatitis B: Challenges, Setbacks, and Breakthroughs

Contact Info

Product

Resources

About